IMS Health Incorporated $1,050,000,000 5.000% Senior Notes due 2026 €625,000,000 3.500% Senior Notes due 2024Purchase Agreement • November 3rd, 2016 • Quintiles IMS Holdings, Inc. • Services-commercial physical & biological research • New York
IMS Health Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this Purchase Agreement (this “Agreement”), to issue and sell to (i) the Purchasers named as Dollar Note Purchasers in Schedule II hereto (the “Dollar Note Purchasers”) an aggregate of $1,050,000,000 principal amount of 5.000% Senior Notes due 2026 (the “Dollar Notes”) and (ii) the Purchasers named as Euro Note Purchasers in Schedule II hereto (the “Euro Note Purchasers” and, together with the Dollar Note Purchasers, the “Purchasers”) an aggregate of €625,000,000 principal amount of 3.500% Senior Notes due 2024 (the “Euro Notes” and, together with the Dollar Notes, the “Securities”). The Securities will be issued by the Company pursuant to the Indenture (as defined herein), among the Company, the Guarantors (as defined herein) and U.S. Bank National Association, as trustee (the “Trustee”). Goldman, Sachs & Co. is acting as representative (the “Representative”) in con
Quintiles Transnational HOLDINGS INC. AWARD AGREEMENTAward Agreement • November 3rd, 2016 • Quintiles IMS Holdings, Inc. • Services-commercial physical & biological research • North Carolina
THIS AWARD AGREEMENT (this “Agreement”) is made by and between Quintiles Transnational Holdings Inc., a North Carolina corporation (the “Company”), and [_________] (the “Participant”) pursuant to the provisions of the Quintiles Transnational Holdings Inc. 2013 Stock Incentive Plan (the “Plan”), which is incorporated herein by reference. Capitalized terms not defined in this Agreement shall have the meanings given to them in the Plan.
